A Phase II, Single-blind, Randomised, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura

Trial Profile

A Phase II, Single-blind, Randomised, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Caplacizumab (Primary) ; Caplacizumab (Primary)
  • Indications Thrombotic thrombocytopenic purpura
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms TITAN
  • Sponsors Ablynx
  • Most Recent Events

    • 06 Aug 2017 The trial has been discontinued in Belgium.
    • 02 May 2017 Results published in an Ablynx media release.
    • 26 Apr 2017 Results of post-hoc analysis published in the Journal of Thrombosis and Haemostasis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top